Kaleido Biosciences Stock Book Value Per Share
| KLDODelisted Stock | USD 0.01 0.00 0.00% |
Kaleido Biosciences fundamentals help investors to digest information that contributes to Kaleido Biosciences' financial success or failures. It also enables traders to predict the movement of Kaleido Pink Sheet. The fundamental analysis module provides a way to measure Kaleido Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Kaleido Biosciences pink sheet.
Kaleido |
Kaleido Biosciences Company Book Value Per Share Analysis
Kaleido Biosciences' Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
More About Book Value Per Share | All Equity Analysis
Book Value per Share | = | Common EquityAverage Shares |
Current Kaleido Biosciences Book Value Per Share | 0.25 X |
Most of Kaleido Biosciences' fundamental indicators, such as Book Value Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Kaleido Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
CompetitionIn accordance with the recently published financial statements, the book value per share of Kaleido Biosciences is about 0.249 times. This is 114.65% lower than that of the Pharmaceuticals sector and 100.1% lower than that of the Health Care industry. The book value per share for all United States stocks is 99.99% higher than that of the company.
Kaleido Book Value Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Kaleido Biosciences' direct or indirect competition against its Book Value Per Share to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Kaleido Biosciences could also be used in its relative valuation, which is a method of valuing Kaleido Biosciences by comparing valuation metrics of similar companies.Kaleido Biosciences is currently under evaluation in book value per share category among its peers.
Kaleido Fundamentals
| Return On Equity | -5.81 | ||||
| Return On Asset | -1.0 | ||||
| Operating Margin | (79.28) % | ||||
| Current Valuation | (16.73 M) | ||||
| Shares Outstanding | 42.62 M | ||||
| Shares Owned By Insiders | 0.73 % | ||||
| Shares Owned By Institutions | 0.36 % | ||||
| Number Of Shares Shorted | 2.34 M | ||||
| Price To Earning | (1.45) X | ||||
| Price To Book | 0 X | ||||
| Price To Sales | 0.04 X | ||||
| Revenue | 1.1 M | ||||
| Gross Profit | (66.7 M) | ||||
| EBITDA | (85.09 M) | ||||
| Net Income | (90.29 M) | ||||
| Cash And Equivalents | 38.47 M | ||||
| Cash Per Share | 0.90 X | ||||
| Total Debt | 5.55 M | ||||
| Debt To Equity | 2.04 % | ||||
| Current Ratio | 1.42 X | ||||
| Book Value Per Share | 0.25 X | ||||
| Cash Flow From Operations | (77.09 M) | ||||
| Short Ratio | 29.34 X | ||||
| Earnings Per Share | (2.16) X | ||||
| Target Price | 22.0 | ||||
| Number Of Employees | 76 | ||||
| Beta | 0.42 | ||||
| Market Capitalization | 421.96 K | ||||
| Total Asset | 50.14 M | ||||
| Retained Earnings | (197.63 M) | ||||
| Working Capital | 62.54 M | ||||
| Current Asset | 72.93 M | ||||
| Current Liabilities | 10.39 M | ||||
| Z Score | -6.3 | ||||
| Net Asset | 50.14 M |
About Kaleido Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Kaleido Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kaleido Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kaleido Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Other Consideration for investing in Kaleido Pink Sheet
If you are still planning to invest in Kaleido Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kaleido Biosciences' history and understand the potential risks before investing.
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |